
Chinese radiopharmaceutical company registered on 24 January 2000 with the Guangzhou Development Zone market and quality supervision administration, with Hua Ning as legal representative and a scope covering radiopharmaceutical retail, radiopharmaceutical production and drug research. Is a subsidiary of HTA Co., Ltd., whose main business is production and service of radioactive medicines used in early cancer diagnosis and in examination of thyroid disease, diabetes and tumours as well as treatment of thyroid cancer and bone tumours, with products spanning radiopharmaceuticals, radioactive sources, radioactive medical devices and radiolabelled compounds and tracers. Its parent is 69.49 per cent held by China Isotope and Radiation, one of the eight industrial segments of the China National Nuclear Corporation, which is the ultimate controller.
Laissez votre note